Results 31 to 40 of about 39,319 (333)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Cancer Medicine, 2022
Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy
Yuchen Zhang, Panpan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhiming Li, He Huang, Yi Xia, Qingqing Cai   +21 more
doaj   +1 more source

A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.

Blood, 2020
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a
C. Tam, Stephen Samuel Opat, S. D’Sa, W. Jurczak, Hui-Peng Lee, G. Cull, R. Owen, P. Marlton, B. Wahlin, R. G. Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. Castillo, J. Czyż, C. Fernández de Larrea, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trněný, M. Minnema, C. Buske, V. Leblond, J. Trotman, W. Chan, J. Schneider, S. Ro, A. Cohen, Jane E. Huang, M. Dimopoulos   +32 more
semanticscholar   +1 more source

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

Cell Death Discovery, 2022
Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD).
Viktoria Fuhr, Shanice Heidenreich, Mugdha Srivastava, Angela Riedel, Johannes Düll, Elena Gerhard-Hartmann, Andreas Rosenwald, Hilka Rauert-Wunderlich   +7 more
doaj   +1 more source

Ibrutinib for B cell malignancies [PDF]

Experimental Hematology & Oncology, 2014
Research over the role of Bruton's agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765),
Delong Liu, Aileen Novero, Yamei Chen, Yamei Chen, Pavan M Ravella, George Dous   +5 more
openaire   +3 more sources

Drug Review: Ibrutinib [PDF]

Indian Journal of Medical and Paediatric Oncology, 2020
AbstractIbrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy.
openaire   +2 more sources

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma ...
Michael L. Wang, W. Jurczak, M. Jerkeman, J. Trotman, P. Zinzani, D. Belada, C. Boccomini, I. Flinn, P. Giri, A. Goy, P. Hamlin, O. Hermine, J. Hernández‐Rivas, X. Hong, S. Kim, D. Lewis, Y. Mishima, M. Özcan, G. Perini, C. Pocock, Yuqin Song, S. Spurgeon, J. Storring, J. Walewski, Jun Zhu, Rui Qin, T. Henninger, S. Deshpande, A. Howes, S. le Gouill, M. Dreyling   +30 more
semanticscholar   +1 more source

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Journal of Neuroinflammation, 2018
Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling.
Hye Yeon Nam, Jin Han Nam, Gwangho Yoon, Ju-Young Lee, Youngpyo Nam, Hye-Jin Kang, Hyun-Ji Cho, Jeongyeon Kim, Hyang-Sook Hoe   +8 more
doaj   +1 more source

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study

Journal of Clinical Oncology, 2023
PURPOSE To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft ...
D. Miklos, M. Abu Zaid, J. Cooney, J. Albring, M. Flowers, A. Skarbnik, I. Yakoub-Agha, B. Ko, B. Bruno, E. Waller, J. Yared, S. Sohn, C. Bulabois, T. Teshima, D. Jacobsohn, H. Greinix, A. Mokatrin, Yihua Lee, J. Wahlstrom, L. Styles, G. Socié   +20 more
semanticscholar   +1 more source

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Haematologica, 2017
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients.
Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger   +26 more
doaj   +1 more source

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Advances in Hematology, 2022
Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation.
Januario E. Castro, Paula A. Lengerke-Diaz, Juliana Velez Lujan, Michael Y. Choi, Eider F. Moreno-Cortes, Jose V. Forero, Juan Esteban Garcia-Robledo, Chaja Jacobs, Colin McCarthy, Alaina Heinen, Carlos I. Amaya-Chanaga, Thomas J. Kipps   +11 more
doaj   +1 more source